Dow Up1.31% Nasdaq Up2.40%

Franklin Biotechnology Discovery Adv (FTDZX)

160.37 Up 4.25(2.72%) Oct 21

Profile as of Sep 29, 2014Get Profile for:
Franklin Biotechnology Discovery Adv
Franklin Strategic SeriesOne Franklin ParkwaySan Mateo, CA 94403-1906
Phone: 800-632-2301
Fund Overview 
Fund Family:Franklin Templeton Investments
Net Assets:1.59B
Year-to-Date Return:20.48%
Morningstar Rating:4 stars
Fund Inception Date:Sep 1, 2009
Morningstar Style Box 
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Evan S. McCulloch
Lead Manager since Sep 15, 1997
Evan McCulloch is a vice president and portfolio manager for Franklin Advisers, Inc. He is the portfolio manager of the Franklin Biotechnology Discovery Fund. Mr. McCulloch also specializes in research analysis of the health care industry; including biotechnology, pharmaceuticals, health care information systems/internet, and health care providers. Mr. McCulloch joined Franklin Templeton Investments in 1992. He was co-manager of the Franklin Biotechnology Discovery Fund since its inception in 1997 and lead manager of the fund since November 2000. Mr. McCulloch received a bachelor's degree in economics from the University of California at Berkeley. He is a Chartered Financial Analyst (CFA) and a member of the Association for Investment Management and Research (AIMR) and the Security Analysts of San Francisco (SASF).
Investment Information 
Min Initial Investment:1,000,000
Min Initial Investment, IRA:N/A
Min Initial Investment, AIP:N/A
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:N/A
Min Subsequent Investment, AIP:N/A
FTDZX can be purchased from 34 brokerages.

Fund Summary 
The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 15, 2013) : 0.00
Annual Holdings Turnover (Oct 20, 2014) : 48.70%
Average for Category:52.61%
Fees & Expenses 
ExpenseFTDZXCategory Avg
Annual Report Expense Ratio (net):0.80%1.39%
Prospectus Net Expense Ratio:0.80%N/A
Prospectus Gross Expense Ratio:0.80%N/A
Max 12b1 Fee:N/AN/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: N/A2.37%
3 Yr Expense Projection*:255668
5 Yr Expense Projection*:4441,044
10 Yr Expense Projection*:9902,042
* Per $10,000 invested